BACKGROUND: Up to 25% of all acute ischaemic strokes occur during sleep. Because of the unclear time window, patients with stroke on awakening are usually not considered for acute therapy and excluded from most acute treatment trials. AIM: To evaluate the feasibility of magnetic resonance imaging-based intravenous thrombolysis in patients with stroke on awakening in a routine clinical setting. METHODS: Forty-five patients with stroke on awakening clinically qualifying for intravenous thrombolysis and presenting within 6 h after symptom recognition were admitted to our institution between October 2006 and May 2008. Following an institutional protocol, patients received magnetic resonance imaging as a first-line imaging modality and were offered mismatch-based thrombolysis whenever possible. Baseline demographic data, clinical, laboratory and imaging findings were analysed. Outcome was assessed using the modified Rankin Scale score at 3 months. RESULTS: Magnetic resonance imaging screening was feasible in 43/45 patients (96%). After screening, 10 patients (22%) were treated with intravenous thrombolysis. There were no differences between treated and untreated patients regarding cardiovascular risk factors, stroke aetiology, previous prophylactic treatment and symptom recognition to door time or door to imaging time. Outcome was comparable in both groups despite a trend towards more severe strokes in the intravenous thrombolysis group. Only one asymptomatic and no symptomatic haemorrhage were observed. CONCLUSION: Our data demonstrate that magnetic resonance imaging-based thrombolysis is feasible and possibly safe in patients with stroke on awakening (SOA). Randomised clinical trials for patients with stroke on awakening are needed to further test the safety and efficacy of intravenous thrombolysis in this patient group. The results of our study may help to initiate and design such studies.
BACKGROUND: Up to 25% of all acute ischaemic strokes occur during sleep. Because of the unclear time window, patients with stroke on awakening are usually not considered for acute therapy and excluded from most acute treatment trials. AIM: To evaluate the feasibility of magnetic resonance imaging-based intravenous thrombolysis in patients with stroke on awakening in a routine clinical setting. METHODS: Forty-five patients with stroke on awakening clinically qualifying for intravenous thrombolysis and presenting within 6 h after symptom recognition were admitted to our institution between October 2006 and May 2008. Following an institutional protocol, patients received magnetic resonance imaging as a first-line imaging modality and were offered mismatch-based thrombolysis whenever possible. Baseline demographic data, clinical, laboratory and imaging findings were analysed. Outcome was assessed using the modified Rankin Scale score at 3 months. RESULTS: Magnetic resonance imaging screening was feasible in 43/45 patients (96%). After screening, 10 patients (22%) were treated with intravenous thrombolysis. There were no differences between treated and untreated patients regarding cardiovascular risk factors, stroke aetiology, previous prophylactic treatment and symptom recognition to door time or door to imaging time. Outcome was comparable in both groups despite a trend towards more severe strokes in the intravenous thrombolysis group. Only one asymptomatic and no symptomatic haemorrhage were observed. CONCLUSION: Our data demonstrate that magnetic resonance imaging-based thrombolysis is feasible and possibly safe in patients with stroke on awakening (SOA). Randomised clinical trials for patients with stroke on awakening are needed to further test the safety and efficacy of intravenous thrombolysis in this patient group. The results of our study may help to initiate and design such studies.
Authors: M Wintermark; P C Sanelli; G W Albers; J Bello; C Derdeyn; S W Hetts; M H Johnson; C Kidwell; M H Lev; D S Liebeskind; H Rowley; P W Schaefer; J L Sunshine; G Zaharchuk; C C Meltzer Journal: AJNR Am J Neuroradiol Date: 2013-08-01 Impact factor: 3.825
Authors: Branko N Huisa; David S Liebeskind; Rema Raman; Qing Hao; Brett C Meyer; Dawn M Meyer; Thomas M Hemmen Journal: J Stroke Cerebrovasc Dis Date: 2012-02-09 Impact factor: 2.136
Authors: I Mourand; D Milhaud; C Arquizan; K Lobotesis; R Schaub; P Machi; X Ayrignac; O F Eker; A Bonafé; V Costalat Journal: AJNR Am J Neuroradiol Date: 2015-11-05 Impact factor: 3.825
Authors: Max Wintermark; Pina C Sanelli; Gregory W Albers; Jacqueline A Bello; Colin P Derdeyn; Steven W Hetts; Michele H Johnson; Chelsea S Kidwell; Michael H Lev; David S Liebeskind; Howard A Rowley; Pamela W Schaefer; Jeffrey L Sunshine; Greg Zaharchuk; Carolyn C Meltzer Journal: J Am Coll Radiol Date: 2013-08-13 Impact factor: 5.532